AlloVir, Inc. (NASDAQ:ALVR) insider Beek Jeroen B. Van sold 15,205 shares of AlloVir stock in a transaction that occurred on Tuesday, August 17th. The shares were sold at an average price of $17.82, for a total transaction of $270,953.10. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of ALVR opened at $23.48 on Wednesday. AlloVir, Inc. has a fifty-two week low of $16.66 and a fifty-two week high of $48.96. The stock has a market capitalization of $1.53 billion, a PE ratio of -9.07 and a beta of 3.35. The company’s fifty day moving average is $19.76 and its 200 day moving average is $21.79.
AlloVir (NASDAQ:ALVR) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.14). Analysts anticipate that AlloVir, Inc. will post -1.99 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of ALVR. BlackRock Inc. increased its position in AlloVir by 30.8% during the first quarter. BlackRock Inc. now owns 2,373,060 shares of the company’s stock valued at $55,530,000 after acquiring an additional 558,523 shares during the last quarter. JPMorgan Chase & Co. increased its position in AlloVir by 6,076.4% during the first quarter. JPMorgan Chase & Co. now owns 498,498 shares of the company’s stock valued at $11,665,000 after acquiring an additional 490,427 shares during the last quarter. Lido Advisors LLC bought a new position in AlloVir during the second quarter valued at $8,284,000. Goldman Sachs Group Inc. increased its position in AlloVir by 826.0% during the first quarter. Goldman Sachs Group Inc. now owns 280,310 shares of the company’s stock valued at $6,559,000 after acquiring an additional 250,039 shares during the last quarter. Finally, Woodline Partners LP increased its position in AlloVir by 20.8% during the second quarter. Woodline Partners LP now owns 1,425,885 shares of the company’s stock valued at $28,147,000 after acquiring an additional 245,951 shares during the last quarter. Institutional investors and hedge funds own 40.54% of the company’s stock.
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Further Reading: What is Cost of Capital?
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.